Highlights and Quick Summary
- Annual 3Y Operating CF Growth (CAGR) for 2021 was 0.0% (a NaN% decrease from previous year)
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical 3Y Operating CF Growth (CAGR) of Terns Pharmaceuticals, Inc.Most recent 3Y Operating CF Growth (CAGR)of TERN including historical data for past 10 years.
Interactive Chart of 3Y Operating CF Growth (CAGR) of Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc. 3Y Operating CF Growth (CAGR) for the past 10 Years (both Annual and Quarterly)
Business Profile of Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.